Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL)
Overview
Authors
Affiliations
Glycosylation, the posttranslational linking of sugar molecules to proteins, is notoriously altered during tumor transformation. More specifically in carcinomas, GalNAc-type -glycosylation, is characterized by biosynthetically immature truncated glycans present on the cancer cell surface, which profoundly impact anti-tumor immune recognition. The tumor-associated glycan pattern may thus be regarded as a biomarker of immune modulation. In epithelial ovarian cancer (EOC) there is a particular lack of specific biomarkers and molecular targets to aid early diagnosis and develop novel therapeutic interventions. The aim of this study was to investigate the ovarian cancer -glycoproteome and identify tumor-associated glycoproteins relevant in tumor-dendritic cell (DC) interactions, mediated by macrophage galactose-like C type lectin (MGL), which recognizes the tumor-associated Tn -glycan. Lectin weak affinity chromatography (LWAC) was employed to probe the -glycopeptidome by MGL and agglutinin (VVA) lectin using glycoengineered ovarian cancer cell lines and ovarian cancer tissues as input material. Biochemical and bioinformatics analysis gave information on the glycan arrangement recognized by MGL in tumor cells. The potential MGL binders identified were located, as expected, at the cell membrane, but also within the intracellular compartment and the matrisome, suggesting that MGL in vivo may play a complex role in sensing microenvironmental cues. The tumor glycoproteins binders for MGL may become relevant to characterize the interaction between the immune system and tumor progression and contribute to the design of glycan targeting-based strategies for EOC immunotherapeutic interventions.
The role of MUC16 in tumor biology and tumor immunology in ovarian cancer.
Yang N, Zhou X, Gong Y, Deng Z BMC Cancer. 2025; 25(1):294.
PMID: 39972413 PMC: 11837316. DOI: 10.1186/s12885-025-13461-0.
Colaco M, Cruz M, de Almeida L, Borges O Pharmaceutics. 2024; 16(10).
PMID: 39458637 PMC: 11510408. DOI: 10.3390/pharmaceutics16101308.
Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects.
Wolters-Eisfeld G, Oliveira-Ferrer L Semin Immunopathol. 2024; 46(6):16.
PMID: 39432076 PMC: 11493797. DOI: 10.1007/s00281-024-01025-6.
Biological function of sialic acid and sialylation in human health and disease.
Zhu W, Zhou Y, Guo L, Feng S Cell Death Discov. 2024; 10(1):415.
PMID: 39349440 PMC: 11442784. DOI: 10.1038/s41420-024-02180-3.
Mass Spectrometry Strategies for -Glycoproteomics.
Helms A, Brodbelt J Cells. 2024; 13(5.
PMID: 38474358 PMC: 10930906. DOI: 10.3390/cells13050394.